Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders

Abstract

Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders.

1 . A method for treating a mood disorder in a human in need thereof comprising administering to the human a therapeutically effective amount of an amylin agonist analog comprising the amino acid sequence of SEQ ID NO:159 to treat the mood disorder. 
     
     
         2 . The method of  claim 1 , wherein the mood disorder is bipolar disorder. 
     
     
         3 . The method of  claim 1 , wherein the mood disorder is major depressive disorder, dysthymic disorder, bipolar I disorder, bipolar II disorder, or cyclothymic disorder. 
     
     
         4 . A method for treating a mood disorder, an anxiety disorder, or schizophrenia in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an amylin agonist analog comprising an amino acid sequence having at least 90% sequence identity to SEQ ID NO:159 to treat the mood disorder, the anxiety disorder, or schizophrenia. 
     
     
         5 . The method of  claim 4 , wherein the amylin agonist analog comprises the amino acid sequence of SEQ ID NO: 156, 157, 158, 159, 160, 162, 163, 164, 170, 171, 180, 181, 183, 184, 185, 186, 187, 189, 190, 192, 194, 195, 196, 197, 198, 199, 200, 201, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 222, 223, 227, 228, 234, 235, 241, 246, 249, or 253. 
     
     
         6 . The method of  claim 4 , wherein the amylin agonist analog comprises an amino acid sequence having at least 92% sequence identity to SEQ ID NO:159. 
     
     
         7 . The method of  claim 6 , wherein the amylin agonist analog comprises the amino acid sequence of SEQ ID NO: 156, 157, 158, 159, 160, 162, 163, 164, 170, 180, 181, 184, 185, 187, 190, 194, 195, 196, 197, 201, 206, 207, 208, 209, 211, 212, 213, 214, 215, 217, 218, 234, 235, 246, or 253. 
     
     
         8 . The method of  claim 4 , wherein the amylin agonist analog comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO:159. 
     
     
         9 . The method of  claim 8 , wherein the amylin agonist analog comprises the amino acid sequence of SEQ ID NO: 159, 160, 180, or 253. 
     
     
         10 . The method of  claim 4 , wherein the amylin agonist analog comprises the amino acid sequence of SEQ ID NO:159. 
     
     
         11 . The method of  claim 4 , wherein the method is for treating the mood disorder. 
     
     
         12 . The method of  claim 11 , wherein the mood disorder is depression or bipolar disorder. 
     
     
         13 . The method of  claim 11 , wherein the mood disorder is major depressive disorder, dysthymic disorder, bipolar I disorder, bipolar II disorder, or cyclothymic disorder. 
     
     
         14 . The method of  claim 4 , wherein the method is for treating the anxiety disorder. 
     
     
         15 . The method of  claim 14 , wherein the anxiety disorder is obsessive-compulsive disorder, panic disorder, a phobia, post-traumatic stress disorder, acute stress disorder, or generalized anxiety disorder. 
     
     
         16 . The method of  claim 4 , wherein the method is for treating schizophrenia. 
     
     
         17 . The method of  claim 16 , wherein the schizophrenia is paranoid schizophrenia, disorganized schizophrenia, catatonic schizophrenia, residual schizophrenia, a schizoaffective disorder, or undifferentiated schizophrenia. 
     
     
         18 . The method of  claim 4 , further comprising administering to the subject at least one other psychiatric medication. 
     
     
         19 . The method of  claim 4 , further comprising administering to the subject (i) a tricyclic antidepressant; (ii) a monoamine oxidase inhibitor; (iii) a selective serotonin reuptake inhibitor; (iv) a serotonin and noradrenaline reuptake inhibitor; (v) a second generation antipsychotic medication; or (vi) a combination of two or more thereof 
     
     
         20 . A method for treating a mood disorder, an anxiety disorder, or schizophrenia in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an amylin agonist comprising the amino acid sequence of any one of SEQ ID NOs:1-31, 33, 35-67, 80-83, and 86-253 to treat the mood disorder, the anxiety disorder, or schizophrenia.